1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Epiomic Epidemiology Series: Familial Dyslipidaemia Forecast in 8 Major Markets 2016-2026

Epiomic Epidemiology Series: Familial Dyslipidaemia Forecast in 8 Major Markets 2016-2026

  • March 2016
  • -
  • Black Swan Analysis Ltd
  • -
  • 40 pages

Summary

Table of Contents

Search Inside

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Dyslipidaemia (Familial Type) in 8 Major Markets

Dyslipidaemia is defined as individuals with elevated triglycerides, low density lipoprotein or total cholesterol, or with lowered levels of high density lipoprotein. Many patients meet the requirements of Dyslipidaemia on more than one factor.
Dyslipidaemia can be divided into two forms: familial (primary) or acquired (secondary). Primary causes are single or multiple gene mutations and secondary causes are mainly a result of a sedentary lifestyle, with diets that consist largely of saturated fats, cholesterol and trans-fats.

This report provides the current prevalent population for Dyslipidaemia, with primary focus on the familial/primary type, across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Familial Dyslipidaemia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Dyslipidaemia include:

-Diabetes & metabolic syndrome
-Paresthesias
-Coronary artery disease
-Peripheral arterial disease
-Aortic stenosis (familial)
-Xanthomas (familial)

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

-Able to quantify patient populations in global Dyslipidaemia’s market to target the development of future products, pricing strategies and launch plans.
-Gain further insight into the prevalence of the subdivided types of Dyslipidaemia and identify patient segments with high potential.
-Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
-Provide a level of understanding on the impact from specific co-morbid conditions on Dyslipidaemia’s prevalent population.
-Identify sub-populations within Dyslipidaemia which require treatment.
-Gain an understanding of the specific markets that have the largest number of Dyslipidaemia patients.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Idiopathic Pulmonary Fibrosis Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Global Idiopathic Pulmonary Fibrosis Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • $ 6500
  • Industry report
  • February 2017
  • by P&S Market Research

Pipeline Overview Idiopathic pulmonary fibrosis (IPF) is referred to as progressive and chronic interstitial pneumonia without known cause. Pulmonary fibrosis is a disease in which tissue profound in lungs ...

Chronic Kidney Disease (CKD) Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Chronic Kidney Disease (CKD) Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • March 2017
  • by Transparency Market Research

Chronic Kidney Disease (CKD) Drugs Market (Drug Class - ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers, Erythropoiesis - stimulating Agents (ESAs), and Diuretics; ...

Cholesterol Screening/ Cholesterol Lab Testing Services Market by Type of Customer, Geography & Qualitative Assessment - Forecasts to 2021

Cholesterol Screening/ Cholesterol Lab Testing Services Market by Type of Customer, Geography & Qualitative Assessment - Forecasts to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global cholesterol testing services market is expected to reach USD 17.5 billion by 2021 from USD 11.9 billion in 2016, growing at a CAGR of 8% during the forecast period. This market is segmented ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.